Baccharis Allergy Shots (SCIT)
Baccharis allergy shots (SCIT) target a salt-tolerant coastal marsh shrub whose male plants release wind-dispersed pollen October through November — weeks after ragweed season ends — creating a sequential two-punch fall allergy calendar for patients from Charleston to Galveston. The conspicuous fluffy white plumes patients see in fall are female seed structures, not the allergenic pollen.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Baccharisis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Baccharis Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to baccharis — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of baccharis allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of baccharis immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of baccharis extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for baccharis allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing baccharis extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription baccharis immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat baccharis allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Baccharis?
The biology, taxonomy, and clinical fingerprint of Baccharis — the foundation of how SCIT targets it.
Baccharis halimifolia female plants produce conspicuous fluffy white seed plumes in fall — these are seeds, not pollen; the wind-borne pollen is released by separate male plants in late September through November
- Scientific name
- Baccharis halimifolia
- Family
- AsteraceaeComposite / Daisy family
- Type
- Dioecious perennial shrub pollen
- Native to
- Atlantic and Gulf Coast brackish-marsh zones, Massachusetts to Texas
- Allergen proteins
- No WHO/IUIS-characterized allergens for Baccharis spp.Modern literature essentially limited to extract-level skin prick test data — molecular research extremely sparseWestern relative B. salicifolia (mule fat) bimodal pollen season in coastal Southern California and Sonoran Desert riparian zones
- Particle size
- N/A — uncharacterized
- Avoidance difficulty
- Very difficult
How Baccharis Allergy Presents
Symptoms by body system — useful for distinguishing Baccharis sensitivity from overlapping allergies and infections.
Respiratory
- Late-fall rhinitis October through November for Atlantic and Gulf coastal residents — beginning after ragweed season has ended
- Nasal congestion and sneezing in Mobile, Charleston, Savannah, Tampa, Galveston, and Brownsville during October–November
- Allergic asthma exacerbation in the late-fall period for coastal patients who thought their season was ending
- Post-nasal drip and throat clearing persisting into November and sometimes December on the Gulf Coast
- Symptoms intensified for patients living within 1–2 miles of tidal marsh or brackish coastal wetlands
Ocular
- Allergic conjunctivitis October–November in coastal SE and Gulf patients
- Bilateral tearing and itching coinciding with the transition from ragweed to baccharis season
- Symptoms continuing when patients expect fall allergy to resolve after ragweed peak
- Higher exposure near coastal marshes, tidal flats, and salt-spray roadsides
Skin
- Potential Asteraceae sesquiterpene lactone contact dermatitis from direct plant handling
- Atopic dermatitis flare during the October–November coastal pollen peak
- OAS from Asteraceae pan-allergens uncharacterized but theoretically possible
Systemic
- Fatigue and sleep disruption from prolonged coastal fall allergy — the sequential ragweed (Aug–Sept) then baccharis (Oct–Nov) pattern creates a 3–4 month continuous season
- Holiday-season symptoms in coastal SE/Gulf states that surprise patients expecting fall allergy season to have ended
- Baccharis is invasive in coastal Australia and parts of Europe — expanding global allergological relevance
- Patients within 1–2 miles of tidal marsh have substantially higher cumulative exposure
When a Charleston patient still has nasal symptoms in November after ragweed counts have dropped to zero, baccharis is usually the answer — and they are looking at it bloom right outside their door without knowing what it is.
When & Where Baccharis Peaks
Allergen intensity by month and by state. Useful for timing SCIT start dates and travel planning.
12-Month Intensity
Peak: October through November on Atlantic seaboard; extending into December on the Gulf Coast· ~8–10 weeks of pollen release from male plants; the sequential ragweed + baccharis pattern creates a 3–4 month total coastal fall allergy season
US Exposure Map
7 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Moderate
- MA:
- Moderate
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Moderate
- CT:
- Moderate
- RI:
- Moderate
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Moderate
- MD:
- Moderate
- DE:
- Moderate
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Moderate
- SC:
- High
- OK:
- Low
- LA:
- High
- MS:
- High
- AL:
- High
- GA:
- High
- TX:
- High
- FL:
- High
- AK:
- Low
- HI:
- Low
What Baccharis Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Baccharis is in tribe Astereae (same tribe as goldenrod and asters) — but unlike goldenrod, B. halimifolia is wind-pollinated and a legitimate aeroallergen; molecular cross-reactivity data are absent due to uncharacterized allergens, but clinical co-sensitization with ragweed, dog-fennel, and marshelder is high in coastal Southeast patients.
Sequential coastal season — ragweed August–September, baccharis October–November; co-sensitization common in Gulf patients
Both extend the Southeast fall season; often co-included in Gulf coastal fall-weed vials
Is SCIT Right for Your Baccharis Allergy?
Answer five questions to assess whether baccharis SCIT is likely appropriate for your Atlantic or Gulf Coast fall allergy profile.
Do you live within a few miles of the Atlantic or Gulf Coast, particularly near marshes, tidal flats, or salt-spray roadsides?
The Baccharis SCIT Protocol
Baccharis SCIT uses non-standardized B. halimifolia extract (W/V labeled); no WHO/IUIS allergens are characterized and no SCIT-specific RCT has been published. Clinical use in coastal Southeast allergy practices combines it in a Gulf/Atlantic late-fall-weed vial with short ragweed, dog-fennel, marshelder, and cocklebur.
Progressive dose escalation with mandatory 30-minute post-injection observation. Build-up initiated by June allows approaching maintenance before the September–October baccharis onset. The baccharis component is combined with ragweed, dog-fennel, and marshelder in a coastal fall-weed vial.
Ongoing maintenance injections. The October–November symptom window is the primary endpoint for confirming baccharis component effectiveness. Perennial maintenance is appropriate for coastal Louisiana and Florida patients with extended seasons.
After successful completion, durable tolerance is expected. Patients in coastal areas with continuing high exposure may benefit from extended maintenance.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Baccharis SCIT
No published RCT evaluates SCIT specifically for Baccharis halimifolia. Clinical use rests on documented sensitization rates in coastal Southeast populations and the general AAAAI/ACAAI Practice Parameter framework (Cox 2011) for non-standardized weed SCIT.
- Sensitization rate in coastal SE/Gulf fall-symptomatic adults11%Regional NAB / Gulf-Atlantic coastal allergy clinic data — 8–14% of fall-symptomatic adults show positive baccharis reactivity
- Weeks by which baccharis extends the fall allergy season beyond ragweed6%Regional aerobiological monitoring — sequential ragweed (Aug–Sept) then baccharis (Oct–Nov) pattern documented in Atlantic and Gulf Coast NAB stations; 6–8 week season extension
No baccharis-specific SCIT RCT has been published. The evidence base is limited to sensitization data and aerobiology. The clinical value proposition is clear — extending fall allergy treatment coverage to the October–November window that standardized ragweed products (Ragwitek) cannot address — but patients should be informed of the limited evidence before starting therapy.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Baccharis SCIT Side Effects
Baccharis SCIT follows the standard inhalant SCIT safety profile with mandatory 30-minute post-injection observation.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling | Rate 30–50% | Mild |
Injection-site itching | Rate 20–40% | Mild |
Injection-site redness | Rate 20–35% | Mild |
Large local reaction (>5 cm) | Rate 5–10% | Moderate |
Systemic reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis/conjunctivitis flare | Rate 1–3% | Mild |
Generalized urticaria | Rate 0.1–0.5% | Moderate |
Mild asthma exacerbation | Rate 0.1–0.5% | Moderate |
Anaphylaxis Epinephrine available at all SCIT sites; 30-minute observation mandatory | Rate <0.01% per injection | Severe |
Baccharis SCIT safety is consistent with the general inhalant SCIT record; no baccharis-specific safety concerns beyond standard protocol requirements have been identified.
SCIT vs Alternatives for Baccharis
Coastal patients with baccharis sensitization and extended fall symptoms typically receive a combined coastal fall-weed SCIT vial rather than baccharis alone, available at home through Curex; generic SLIT drops or medications are the main alternatives.
| Criterion | At-Home SCIT (Curex)Best | SLIT drops/tablets | Avoidance | Medications |
|---|---|---|---|---|
| Effectiveness | Extrapolated — no baccharis RCT | Extrapolated evidence | Very difficult — dominant coastal marsh shrub | Symptom suppression only |
| 5-yr cost | $3,500–$8,000 out-of-pocket | Daily drops (varies by pharmacy) | Low direct cost | $300–$1,200/year |
| Duration | 3–5 years | 3–5 years | Seasonal | Daily in season |
| Convenience | At-home self-injection; weekly then monthly | Daily drops at home | Restricts coastal outdoor activity Oct–Nov | Convenient but 3–4 month burden |
| Safety | Systemic reaction <0.01%/injection | Lower systemic risk | Complete | Well-tolerated |
| Lasting effect | Durable benefit expected | Durable benefit expected | No lasting effect | No lasting effect |
At-Home SCIT (Curex)Best
SLIT drops/tablets
Avoidance
Medications
For coastal patients in low-population ZIP codes from Apalachicola to Cameron Parish who are far from allergy clinics, Curex delivers an at-home allergy shot with pricing confirmed in a current program quote — a personalized serum compounded to USP <797> covering the complete coastal Gulf/Atlantic fall-weed complex including baccharis, ragweed, dog-fennel, and marshelder in a single formulation, with a prescribed epinephrine auto-injector confirmed on hand and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff — no weekly clinic trips required.
What Baccharis SCIT Actually Costs
Baccharis SCIT as a component of a coastal fall-weed vial is typically covered under standard allergy immunotherapy benefits when a board-certified allergist documents sensitization; coverage depends on plan deductible and co-insurance. Curex at-home IgE testing identifies specific baccharis sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your baccharis allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Baccharis SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
The conspicuous fluffy white silk-like plumes that cover baccharis (groundsel-tree) shrubs in October and November are FEMALE seed structures — achenes with silky pappus hairs that help seeds disperse by wind. They are NOT the allergenic component. Baccharis is dioecious — male and female flowers occur on separate plants. The actual allergenic pollen is released by male plants in late September through November and is not visually distinctive. Many patients blame the white fluffy plumes for their allergy, not realizing they are looking at seeds while being exposed to invisible pollen from nearby male plants.
If you live near the Atlantic or Gulf Coast, late-fall symptoms that persist after ragweed season ends are most likely driven by one or more of three weeds: baccharis (peaking October–November), dog-fennel (peaking October–November in Florida and the Gulf states), and marshelder (peaking August–October in the coastal Southeast). The sequential exposure pattern — short ragweed August–September, followed by these late-fall weeds — creates a continuous 3–4 month coastal fall allergy season. Patients who receive only ragweed treatment (Ragwitek or ragweed SCIT) may still experience significant symptoms October–November because those treatments don't address baccharis or dog-fennel sensitization.
Baccharis halimifolia is sometimes called eastern saltbush or groundsel-tree because of its salt-tolerant coastal habitat — but it is a different plant from the true saltbushes (Atriplex species, Amaranthaceae), which are taxonomically unrelated. Atriplex saltbushes are major aeroallergens in the Western US arid zones and have different allergen proteins. The naming overlap can cause confusion when patients look up their test results or allergy panel. Baccharis is in family Asteraceae while Atriplex is in Amaranthaceae; if your allergy testing shows saltbush reactivity in the context of a Western US panel, that likely refers to Atriplex, not Baccharis.
Baccharis halimifolia (eastern saltbush, groundsel-tree) ranges from Massachusetts and southern New England south along the Atlantic Coast through Florida and along the Gulf Coast to Texas and Mexico. It grows in brackish tidal marshes, salt-spray roadsides, and coastal scrub throughout this range. Outside the US, B. halimifolia has become invasive in coastal Australia (declared noxious in New South Wales) and parts of Europe, where its allergological significance is expanding. The western US has a different dominant species — B. salicifolia (mule fat, seepwillow) — which dominates Sonoran Desert riparian zones and coastal Southern California, with a bimodal spring and fall pollen season.
Baccharis and goldenrod are both in tribe Astereae (Asteraceae family), bloom simultaneously in October, and share a bright fall appearance that gets them confused. The critical difference is pollination mode: goldenrod is insect-pollinated, produces heavy sticky pollen designed for bee transport, and is not a real respiratory aeroallergen. Baccharis halimifolia, by contrast, is wind-pollinated — it is dioecious with separate male plants releasing lightweight airborne pollen — and is a confirmed respiratory allergen with documented sensitization rates of 8–14% in coastal Southeast populations. Baccharis is a legitimate target for fall allergy evaluation; goldenrod is not.
Baccharis SCIT as a component of a coastal Southeast fall-weed vial is typically covered by major US insurers under standard allergy immunotherapy benefits when a board-certified allergist documents sensitization through skin prick or specific IgE testing. Coverage applies to injection administration (CPT 95115, 95117) and extract preparation (CPT 95165). The non-standardized nature of the extract does not typically affect coverage decisions. Plan deductibles and co-insurance determine out-of-pocket costs; prior authorization may be required. Confirming benefits before starting the build-up series is recommended.
Patients typically begin experiencing some symptom reduction in the first treated October–November season after completing build-up. Benefit usually increases progressively over years two and three as tolerance consolidates. The specific improvement expected is in the late-fall window — October and November — when baccharis is the dominant aeroallergen; ragweed-season (August–September) improvement depends on whether the vial includes ragweed extract as well. Most patients in a combined coastal fall-weed vial program see overall improvement across the entire August–November season. Complete relief in the first year is uncommon; the strongest benefit is typically seen at the 2–3 year mark.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.